Who
Mahesh Patel V
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Lipocine.
In numbers
- Trades disclosed
- 73
- Buys
- 18
- Sells
- 4
- Bought
- $592K
- Sold
- $127K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 10 Dec 2013
- Last trade
- 29 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 30 Jun 2026 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $131K52,781 at $2.49 | filing |
| 29 Jun 2026filed 30 Jun 2026 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $131K52,781 at $2.49 | filing |
| 6 Apr 2026filed 6 Apr 2026 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $51K25,000 at $2.03 | filing |
| 6 Apr 2026filed 6 Apr 2026 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $51K25,000 at $2.03 | filing |
| 2 Apr 2026filed 2 Apr 2026 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $51K25,000 at $2.02 | filing |
| 2 Apr 2026filed 2 Apr 2026 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $51K25,000 at $2.02 | filing |
| 2 Jan 2026filed 5 Jan 2026 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $200K25,000 at $8.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $200K25,000 at $8.00 | filing |
| 18 Dec 2025filed 19 Dec 2025 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $36K8,629 at $4.20 | filing |
| 2 Jan 2025filed 2 Jan 2025 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $80K16,371 at $4.86 | filing |
| 23 Dec 2024filed 2 Jan 2025 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $50K10,320 at $4.80 | filing |
| 23 Dec 2024filed 30 Dec 2024 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $128K26,691 at $4.80 | filing |
| 8 Mar 2024filed 12 Mar 2024 | LPCN LipocineBiotechnology | SEC FORM 4 Code A | —4,893 at $0.00 | filing |
| 25 May 2023filed 25 May 2023 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $44K8,706 at $5.03 | filing |
| 24 Mar 2023filed 24 Mar 2023 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $48K150,000 at $0.32 | filing |
| 17 Mar 2023filed 17 Mar 2023 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $17K50,000 at $0.33 | filing |
| 3 Jan 2023filed 4 Jan 2023 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $123K300,000 at $0.41 | filing |
| 22 Dec 2022filed 22 Dec 2022 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $46K112,500 at $0.41 | filing |
| 14 Nov 2022filed 14 Nov 2022 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $29K75,000 at $0.39 | filing |
| 27 Sep 2022filed 27 Sep 2022 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $41K100,000 at $0.41 | filing |
News
Lipocine (NASDAQ:LPCN) vs. Theravance Biopharma (NASDAQ:TBPH) Head to Head ReviewLPCN · tickerreport.com · 22 Oct 2026Lipocine (NASDAQ:LPCN) & Harmony Biosciences (NASDAQ:HRMY) Head-To-Head AnalysisLPCN · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Mahesh Patel V; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.